International Stem Cell Corp., of Carlsbad, Calif., reported positive data from a study of safety and efficacy of human parthenogenic stem cells in a primate model of Parkinson's disease at the American Academy of Neurology meeting in San Diego

Sistemic Ltd., of Glasgow, UK, inked a deal with Progenitor Cell Therapy (PCT), a subsidiary of NeoStem Inc., of New York, to initiate evaluation studies on Sistemic's SistemQC stem cell characterization technology...The studies are designed to allow PCT to evaluate the applicability of SistemQC technology in stem cell characterization employing Sistemic's miRNA profiling system and analytical approaches to product miRNA panels

Their work appeared in the March 7, 2013, issue of Cell Stem Cell

Stem Cell Therapeutics Corp., of Toronto, said it closed its prospectus offering of about 12.3 million units priced at C25 cents (US24 cents) each for aggregate gross proceeds of $3.1 million

International Stem Cell Corp., of Carlsbad, Calif., said its method of deriving neuronal cells for the treatment of Parkinson's disease was published in Scientific Reports...ISCO is developing a treatment for Parkinson's based on replacing the lost neurons with new neuronal cells derived from human parthenogenetic stem cells

stem cells 11/21/12 Vaccibody A/S (Oslo, Norway) Norwegian Research Council's Program for Innovation €2 ($2.54) Grant To develop a therapeutic vaccine, VB10.16, against precancerous lesions of the cervix 11/13/12 DECEMBER Acadia Pharmaceuticals Inc. (San Diego) Fast Forward LLC (established by the National Multiple Sclerosis Society and EMD Serono, a subsidiary of Darmstadt, Germany-based Merck KGaA) ND Grant To support Acadia's research, in collaboration with the University of California at Los

Instead, patients receive a "stem cell mobilizing" drug, Neupogen (filgrastim, Amgen Inc.), which coaxes stem cells out of their niche in the bone marrow and into the bloodstream, where they can be harvested and then transplanted...Stem cells are rare even in the bone marrow, and rarer still in the blood

International Stem Cell Corp., of Carlsbad, Calif., raised $1 million from a number of existing longstanding investors through a private placement on the same terms as the transaction with management reported on Jan. 22

The product is in pivotal testing for use as a conditioning treatment prior to autologous stem cell transplant in patients with multiple myeloma

Advanced Cell Technology Inc., of Santa Monica, Calif., said an independent data and safety monitoring board authorized the firm to move forward with enrollment and treatment of patients in the next cohort of each of its three ongoing trials of human embryonic stem cell-derived retinal pigment epithelial cells for eye diseases

Sistemic Ltd., of Glasgow, UK, inked a deal with Progenitor Cell Therapy (PCT), a subsidiary of NeoStem Inc., of New York, to initiate evaluation studies on Sistemic's SistemQC stem cell characterization technology...The studies are designed to allow PCT to evaluate the applicability of SistemQC technology in stem cell characterization employing Sistemic's miRNA profiling system and analytical approaches to product miRNA panels

has raised A$170 million (US$174.6 million) in a private placing, bringing total cash reserves for the stem cell specialist to A$332 million and providing funding for a Phase III trial in treating degenerating spinal discs

AmVac AG, of Zug, Switzerland, disclosed new preclinical data on its vaccine candidate AMV602 for the prevention of infections caused by respiratory syncytial virus (RSV). Last fall, the company selected the candidate as the most promising for further development among a range of potential leads. In preclinical studies, researchers at the University of Siena, Italy, have confirmed the candidate's excellent safety and efficacy, showing that even reduced doses of AMV602 trigger effective immune

Though total proceeds remain undisclosed, the raise was designed to fund Ambit for at least 12 months, through receipt of top-line data from a planned Phase III trial of quizartinib in relapsed/refractory acute myeloid leukemia (AML) and ongoing Phase I trials of the drug in combination with chemotherapy for front-line therapy and maintenance therapy following hematopoietic stem cell transplantation (HSCT

It has completed Phase II development for the prevention of CMV infection in adult hematopoietic stem cell transplant recipients, and Chimerix is preparing to start the Phase III SUPPRESS study this year

Conventional drug screens will then be performed to discover compounds that prompt those adult stem cells to differentiate, with the aim of finding small molecules that promote the generation of new tissues...The company did that by using embryonic stem cells to generate blood progenitor cells, and using those cells to identify small molecules that induce them to produce neutrophils

has raised A$170 million (US$174.6 million) in a private placing, bringing total cash reserves for the stem cell specialist to A$332 million and providing funding for a Phase III trial in treating degenerating spinal discs

One of the winners in the second round of grants is the quoted stem cell specialist ReNeuron plc...As such, winning the awards is "a strong independent endorsement" of ReNeuron's stem cell development capabilities.

One of the winners in the second round of grants is the quoted stem cell specialist ReNeuron plc...As such, winning the awards is "a strong independent endorsement" of ReNeuron's stem cell development capabilities.